Defining a therapeutic dose of peripheral blood stem cells.
Peripheral blood stem cells (PBSC) are now used extensively to provide rapid and durable hematopoietic reconstitution following supralethal myeloablative therapies. A major clinical issue is the quantitation of the cells responsible for reconstitution. We review here published reports of transplants using the measurement of mononuclear cells and granulocyte-macrophage colony-forming units (CFU-GM) to quantitate PBSC. In addition, we present data from three institutions where hematopoietic recovery is correlated with doses of CFU-GM or CD34+ cells. These data suggest doses of 20 x 10(4) CFU-GM or 2 x 10(6) CD34+ cells/kg body weight that provide rapid engraftment of neutrophils and platelets.
Bender
J G
JG
Applied Sciences Division, Baxter Healthcare Corporation Round Lake, IL.
To
L B
LB
Williams
S
S
Schwartzberg
L S
LS
D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34; D002452:Cell Count; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007958:Leukocyte Count; D009504:Neutrophils / Q000473:pathology; D010976:Platelet Count
D015703:Antigens, CD; D018952:Antigens, CD34